About Our Group About Our Group

Our Businesses Our Businesses

Investor Relations Investor Relations

Sustainability Sustainability

日本語

Otsuka Group News

HOME
Otsuka Group News

Keyword search

Add search criteria

Search by company

Otsuka Holdings
Otsuka Pharmaceutical
Otsuka Pharmaceutical Factory
Taiho Pharmaceutical
Otsuka Warehouse
Otsuka Chemical
Otsuka Foods
Otsuka Medical Devices
Other

Search by category^*

Pharmaceuticals Business
Nutraceuticals Business
Consumer Products Business
Others
Products
R&D
Personnel
Corporate

* Business categories are based on the business segments described in the financial announcements.

Search by release date

-

Showing 81 results

Search by release date:: Jan, 2023 ～ Dec, 2023

August 25, 2023
Taiho Pharmaceutical

Taiho Pharmaceutical and Phost’in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430
August 25, 2023
Otsuka Foods

Otsuka Foods to Revise Price of CRYSTAL GEYSER Product New Price to Take Effect with Deliveries as of October 1, 2023
August 23, 2023
Otsuka Medical Devices

Otsuka Medical Devices and Recor Medical Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
August 14, 2023
Otsuka Pharmaceutical

Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan -EXCITING SUMMER in WAJIKI and ORONAMIN C DRINK PRESENTS Awa Odori Sound Festival-
August 8, 2023
Otsuka Pharmaceutical

Astex Expands Drug Discovery Collaboration With MSD
August 8, 2023
Otsuka Pharmaceutical

POCARI SWEAT X TOKUSHIMA VORTIS Football Dream Project Phase 3 Otsuka Pharmaceutical and Tokushima Vortis collaborate in exchange program for junior football players in Cambodia
August 7, 2023
Taiho Pharmaceutical

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
August 3, 2023
Taiho Pharmaceutical

FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)
August 3, 2023
Otsuka Foods

Otsuka Foods to Launch a Bittersweet Mild Curry for Adults from the Bon Curry Brand, Celebrating Its 55th Anniversary! “Bon Curry GOLD Hojun Demi Curry Shifuku-no-Amakuchi” In Stores from August 28, 2023
August 1, 2023
Taiho Pharmaceutical

European Commission Approves LONSURF® (Trifluridine/tipiracil) in Combination With Bevacizumab in 3rd Line Refractory Metastatic Colorectal Cancer (mCRC)
July 31, 2023
Otsuka Pharmaceutical

Launch of TCRP NEXT, a New Collaboration Aiming to Promote Total Conditioning - Enhancing sustainable international competitiveness and transitioning from high performance to life performance -
July 31, 2023
Otsuka Pharmaceutical

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
July 27, 2023
Otsuka Pharmaceutical

Tokushima Prefecture Signs First Resource Circulation Agreement with Otsuka Pharmaceutical - Promotion of Horizontal PET Bottle Recycling Initiatives -
July 27, 2023
Otsuka Holdings

Otsuka Holdings Selected as a Constituent of ESG Investment Indexes: FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
July 24, 2023
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters into Cooperative Agreement with Ministry of the Environment
July 24, 2023
Otsuka Holdings

Otsuka Group Completes Construction of Energy Management Building ーAdvancing efficiency of group-wide integrated energy management—
July 5, 2023
Taiho Pharmaceutical

European Commission Grants Conditional Marketing Authorization for Taiho’s LYTGOBI® Tablets for the Treatment of Adults With Cholangiocarcinoma
July 5, 2023
Otsuka Foods

Otsuka Foods to Launch Three New Garlic/Spicy Curry Products from the Bon Curry Brand, Celebrating Its 55th Anniversary! “Bon Curry GOLD Umakara Ninniku Hot” “Bon Curry NEO Kogashi Ninniku Yamitsuki Spicy Hot” “Bon Curry NEO Spicy Atohiku Karasa Very Hot”
July 3, 2023
Taiho Pharmaceutical

Taiho Pharmaceutical to Provide Matching Funds to Select Crowdfunded Projects Addressing Issues in the Field of Oncology The Third "Taiho Smile Support"
June 28, 2023
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory receives the Asia-Pacific Gel Immersion Endoscopy New Product Innovation Award of the 2023 Best Practice Award from Frost & Sullivan
June 27, 2023
Otsuka Pharmaceutical

Otsuka Pharmaceutical announces positive results of phase III trial in Japan showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
June 26, 2023
Taiho Pharmaceutical

Taiho Pharmaceutical Obtains Approval in Japan to Manufacture and Market FGFR Inhibitor LYTGOBI ® Tablets 4mg for Unresectable Biliary Tract Cancer Harboring FGFR2 Gene Fusions That Has Progressed After Chemotherapy
June 26, 2023
Taiho Pharmaceutical

CHMP Issues Positive Opinion for Trifluridine/tipiracil (LONSURF®) in Combination With Bevacizumab in 3rd Line Refractory Metastatic Colorectal Cancer (mCRC)
June 26, 2023
Taiho Pharmaceutical

Taiho Pharmaceutical and Kyushu University Launch Joint Research for the Development of Novel Covalent Reactive Groups with a view to advance Covalent Drugs
June 23, 2023
Otsuka Foods

Otsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of August 1, 2023
May 18, 2023
Taiho Pharmaceutical

Taiho Pharmaceutical Enters into a Clinical Trial Agreement with Arcus Biosciences and Gilead Sciences
May 11, 2023
Otsuka Pharmaceutical

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
May 8, 2023
Otsuka Chemical

SynCrest Launches CRDMO Service for Peptide-based Therapeutics - Integrated support across the drug development value chain with continuous flow synthesis -
May 2, 2023
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory completes acquisition of additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited
April 28, 2023
Otsuka Pharmaceutical

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First, Two-month, Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

Otsuka Group News

HOME
Otsuka Group News